Unraveling the directional link between adiposity and inflammation: a bidirectional mendelian randomization approach by Welsh, P. et al.
 
 
 
 
 
 
 
Welsh, P. and Polisecki, E. and Robertson, M. and Jahn, S. and Buckley, 
B.M. and de Craen, A.J.M. and Ford, I. and Jukema, JW and Macfarlane, 
P.W. and Packard, C.J. and Stott, D.J. and Westendorp, R.G.J. and 
Shepherd, J. and Hingorani, A.D. and Smith, G.Y. and Schaefer, E. and 
Sattar, N.A. (2010) Unraveling the directional link between adiposity and 
inflammation: a bidirectional mendelian randomization approach. 
Journal of Clinical Endocrinology and Metabolism, 95 (1). pp. 93-99. 
ISSN 0021-972X 
 
http://eprints.gla.ac.uk/25916/ 
 
Deposited on: 26 April 2010 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Unraveling the Directional Link between Adiposity
and Inflammation: A Bidirectional Mendelian
Randomization Approach
Paul Welsh, Eliana Polisecki, Michele Robertson, Sabine Jahn,
Brendan M. Buckley, Anton J. M. de Craen, Ian Ford, J. Wouter Jukema,
Peter W. Macfarlane, Chris J. Packard, David J. Stott, Rudi G. J. Westendorp,
James Shepherd, Aroon D. Hingorani, George Davey Smith, Ernst Schaefer,
and Naveed Sattar
Division of Cardiovascular and Medical Sciences (P.W., P.W.M., C.J.P., D.J.S., J.S., N.S.), University of
Glasgow, Glasgow G12 8QQ, United Kingdom; Cardiovascular Research Laboratory, Lipid Metabolism
Laboratory (E.P., E.S., S.J.), Jean Mayer United States Department of Agriculture Human Nutrition
Research Center on Aging, Tufts University, Boston, Massachusetts 02111; Robertson Centre for
Biostatistics (M.R., I.F.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; Department of
Pharmacology and Therapeutics (B.M.B), University College Cork, Cork, Ireland; Departments of
Gerontology and Geriatrics (A.J.M.d.C., R.G.J.W.) and Cardiology (J.W.J.), Leiden University Medical
Centre, 2300 RA Leiden, The Netherlands; Division of Population Sciences (A.D.H.), Department of
Epidemiology and Public Health, University College London, London WC1E 6BT, United Kingdom; and
Medical Research Council Centre for Causal Analyses in Translational Epidemiology (G.D.S.), Department
of Social Medicine, University of Bristol, Bristol BS8 1TH, United Kingdom
Context:Associations between adiposity and circulating inflammationmarkers are assumed to be
causal, although the direction of the relationship has not been proven.
Objective: The aim of the study was to explore the causal direction of the relationship between
adiposity and inflammation using a bidirectional Mendelian randomization approach.
Methods: In the PROSPER study of 5804 elderly patients, we related C-reactive protein (CRP) single
nucleotide polymorphisms (SNPs) (rs1800947 and rs1205) and adiposity SNPs (FTO and MC4R) to
body mass index (BMI) as well as circulating levels of CRP and leptin. We gave each individual two
allele scores ranging from zero to 4, counting each pair of alleles related to CRP levels or BMI.
Results:With increasing CRP allele score, therewas a stepwise decrease in CRP levels (P for trend
0.0001) and a 1.98mg/liter difference between extremes of the allele score distribution, but there
was no associated change in BMI or leptin levels (P 0.89). By contrast, adiposity allele score was
associated with 1) an increase in BMI (1.2 kg/m2 difference between extremes; P for trend 0.002);
2) an increase in circulating leptin (5.77 ng/ml difference between extremes; P for trend 0.0027);
and 3) increased CRP levels (1.24 mg/liter difference between extremes; P for trend 0.002).
Conclusions: Greater adiposity conferred by FTO andMC4R SNPs led to higher CRP levels, with no
evidence for any reverse pathway. Future studies should extend our findings to other circulating
inflammatory parameters. This study illustrates the potential power of Mendelian randomization
to dissect directions of causality between intercorrelated metabolic factors. (J Clin Endocrinol
Metab 95: 93–99, 2010)
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Recent research efforts have focused on identifying ge-netic polymorphisms associated with vascular dis-
ease end-points as well as intermediate phenotypes asso-
ciated with higher vascular risk (1, 2). Germline genetic
variation is generally unrelated to lifestyle, socioeco-
nomic, and environmental variables that generate con-
founding in conventional epidemiological approaches (3–5).
Single nucleotide polymorphisms (SNPs) in the C-reactive
protein (CRP) gene have been identified that influence
CRP concentration (6). For instance, on meta-analysis,
CRP SNP rs1800934 (G  C) and rs1205 (C  T) vari-
ants are associated with a per allele decrease of 0.35 mg/
liter (95% confidence intervals, 0.41, 0.28 mg/liter) and
0.38 mg/liter (95% confidence intervals, 0.50, 0.25 mg/
liter) of circulating CRP, respectively (6). More recently,
SNPs in FTO and MC4R have been described that are
robustly associated with body mass index (BMI) (1). For
instance, the rs9939609 (T  A) variant in FTO is asso-
ciated with a 0.36 kg/m2 (range, 0.34–0.46 kg/m2) per-
allele increase in BMI (7). Similar but quantitatively
weaker results have been described for MC4R SNP
rs17782313 (T  C) being associated with BMI (8). Both
of these FTO andMC4R SNPs may increase BMI specif-
ically by increasing appetite and calorific intake (9–12).
These SNPs, which are now widely accepted to be ro-
bustly associated with the phenotypes outlined, may help
provide insight into the causal relationships between obe-
sity and CRP that cannot be addressed by traditional ob-
servational approaches (13, 14). Specifically, it has been
widely reported in cross-sectional studies that CRP is
strongly associated with BMI, waist circumference, and
waist-hip ratio (15). Indeed, recent prospective evidence
shows this to be a relationship independent of physical
fitness (16). In explaining this relationship, it is usually
assumed that endocrinologically active visceral adipose
tissue releases proinflammatory cytokines such as IL-6
and TNF into the circulation, resulting in a low-grade
hepatic acute phase response and, hence, CRP production
(17). Although this mainstream belief is reasonable, it is
also possible that CRP or generalized inflammation itself
may exacerbate deposition of metabolically active fat de-
posits (18); in this regard, the potential physiological roles
ofCRPare still being debated (19–21). The twodirections
of causality are not necessarily mutually exclusive, and
there may be an element of both pathways playing a role
in a potential positive feedback loop, but, as far as we are
aware, this possibility lacks detailed and direct study. In-
tercorrelation between adiposity and inflammation pre-
cludes elucidation of the casual direction of the relation-
ship using conventional epidemiological tools (22).
In the PROSPER (PROspective Study of Pravastatin in
the Elderly at Risk) study of 5804 older men and women
(23), we have measured both CRP and adiposity-associ-
ated genetic variants (FTO andMC4R) in blood samples
taken at baseline, andwe have used the principles ofMen-
delian randomization (MR) (3) to explore the nature and
causal direction of the links between CRP and adiposity.
Although an elderly cohort (70–82 yr old), where itmight
be expected that illness leading to lower BMI is a stronger
phenomenon than in younger cohorts (24, 25) and the
associations of commongenetic variantswith BMImaybe
weaker, we also have measures of leptin in PROSPER, an
adipokine that correlates well with percentage fat mass
(26). Finally, the use of an elderly population allows us to
examine whether FTO and MC4R are associated with
adiposity in the elderly as they are in younger populations
(9–12, 27).
Subjects and Methods
Participants
The protocol of PROSPER (23) and the methods and out-
comes of the main trial have been published (28).
Between December 15, 1997, andMay 7, 1999, we screened
23,770 individuals and randomized 5804 from Scotland, Ire-
land, and The Netherlands. Men and women aged 70–82 yr
were recruited if theyhadeitherpreexistingvasculardisease (cor-
onary, cerebral, or peripheral) or raised risk of such disease be-
cause of smoking, hypertension, or diabetes. Their plasma total
cholesterol had to be between 4.0 and 9.0 mmol/liter and their
fasting triglyceride concentrations less than 6.0 mmol/liter. All
subjectswere given a clinical examination at baseline before ran-
domization, which included drawing of venous blood samples,
measurement of weight, height, and BMI (weight/height2)
among other clinical parameters by health professionals. The
institutional ethics review boards of all centers approved the
protocol, and all participants gave written informed consent.
The protocol was consistent with the Declaration of Helsinki.
Participants were randomly assigned to receive either pravasta-
tin 40mgdaily ormatching placebo.All datawere processed and
analyzed at the Robertson Centre for Biostatistics, University of
Glasgow (Glasgow, UK).
Genotyping
Genotyping of FTO rs9939609 [intronic nucleotide substi-
tution T A; reported minor allele frequency, 0.44 (http://www.
ncbi.nlm.nih.gov/projects/SNP/)] and MC4R rs17782313 [nu-
cleotide substitution (188kb downstream of the melanocortin 4
receptor gene) T  C; reported minor allele frequency, 0.38] as
well as CRP rs1800947 (nucleotide substitution G  C; allele
change CTG  CTC; protein position 184 residue change
Leu  Leu; reported minor allele frequency, 0.08) and rs1205
(untranslated region-3nucleotide change C  T; reported mi-
nor allele frequency, 0.46) nucleotide changes were carried out
using real-timePCRwithTaqManSNPGenotypingAssays from
Applied Biosystems (Foster City, CA) in the collaborating lab-
oratory at Tufts University (Boston, MA) (6–8).
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Laboratory variables
All analyseswere performedonblood samples drawnat base-
line, before participants received study medicine. CRPwas mea-
sured by automated particle-enhanced immunoturbidimetric as-
say (Roche UK, Welwyn Garden City, UK) (29). The relevant
laboratory participates in a national external quality control for
high-sensitivity CRP. Themethod has a lower limit of sensitivity
of 0.1 mg/liter and interassay and intraassay coefficients of vari-
ation of 3%. Leptin was measured by an in-house RIA validated
thoroughly against the commercially available Linco Research
Co. (St. Charles, MO) assay (30). The intra- and interassay co-
efficients of variation were below 7% and below 10%, respec-
tively. The detection limit of the assay was 0.5 ng/ml. Samples
were processed blinded to their identity.
Statistical analysis
The distributions of CRP and leptin were positively skewed;
therefore, a logarithmic transformation was used. Observed ge-
notype frequencies were compared with those expected under
Hardy-Weinberg equilibrium (HWE) using a 2 test. Baseline
characteristics were compared between the levels of SNPs, or
allele scores from a test for trend to give a P value, and where a
significant (P  0.05) trend was found using allele scores, pair-
wise comparisons between individual data points were calcu-
lated between a score of 0 and the other levels of the score.
Relationships between log CRP, log leptin, and BMI were as-
sessed through the use of the Pearson correlation coefficient. To
increase the power of our observations, we assigned every indi-
vidual a score based on genotype ofMC4R and FTO, such that
AA  0 (most common genotype), AB  1, and BB  2 (least
common genotype). By then combining scores for MC4R and
FTO, every individual had an overall allele score ranging from
zero (most common) to 4 (least common). This process was re-
peated for CRP SNPs so that each individual was assigned an
allele score ranging from zero to 4. The assumption of linear dis-
equilibriumwas testedbetween theCRP SNPs andadiposity SNPs,
respectively.Where any evidence of linear disequilibrium existed, a
sensitivity analysiswas carriedout tovalidate the simpleallele score
model,weighting the allele score according to the effect size of each
SNP, using the  coefficient from a regression analysis.
Results
As a continuous variable, log CRP levels were positively
correlated with BMI after adjusting for age, sex, and
smoking status (r  0.252; P  0.0001). After similar
adjustment, log leptin was positively correlated with BMI
as well as log CRP (r 0.658, P 0.0001; and r 0.303,
P  0.0001, respectively).
Considering the SNPs of interest, the polymorphism fre-
quency is displayed in Table 1. None of the four SNPs
showed strong evidence of departure from HWE:
rs1800447, HWE  0.043, P  0.84; rs1205, HWE 
3.615,P0.06;FTO,HWE1.790,P0.18;andMC4R,
HWE  0.463, P  0.50. The CRP SNPs rs1800947 and
rs1205 were in moderate (31) linkage disequilibrium: r2 
0.36, P  0.0001; whereas FTO and MC4R were not in
linkage disequilibrium: r2 0.00096, P 0.94.
As expected, CRP polymorphisms rs1800947 and
rs1205 were associated with circulating levels of CRP
(1.76 and 1.2 mg/liter difference in circulating levels, re-
spectively, comparing homozygotes; both P for trend
0.0001) (Supplementary Table 1, published as supple-
mental data on The Endocrine Society’s Journals Online
web site at http://jcem.endojournals.org). However, nei-
ther polymorphism showed any association with BMI (P
for trend0.78) orwith leptin (P for trend0.69). There
was weak evidence of an association for the FTO variant
with higher BMI (0.4 kg/m2 comparing homozygotes; P
for trend  0.06), and there was some evidence of an
associationofFTOwith leptin (1 ng/ml difference in levels
comparinghomozygotes;P for trend0.02) (Supplemen-
tary Table 1). The MC4R variant showed a somewhat
more robust association with BMI (0.6 kg/m2 comparing
homozygotes;P for trend 0.0017) andweak evidence of
an association with leptin (1.3 ng/ml difference in levels
comparinghomozygotes;P for trend0.06) (Supplemen-
tary Table 2). Both FTO andMC4R showed associations
with circulating levels of CRP (0.34 mg/liter difference in
circulating levels for both SNPs comparing homozygotes;
both P for trend  0.04).
Allele score data
We analyzed the allele scores for CRP SNPs and adi-
posity SNPs to increase the power of our observations.
TABLE 1. Frequency of CRP and adiposity SNPs in PROSPER cohort
Genotype
FTO rs9939609 (n  5724) MC4R rs17782313 (n  5748)
TT TA AA TT TC CC
CRP rs1800947
GG 1116 1330 401 1734 986 140
GC 875 1137 344 1425 806 134
CC 192 247 82 319 182 22
FTO rs9939609 (n  5734) MC4R rs17782313 (n  5759)
CRP rs1205
CC 987 1255 367 1602 890 127
CT 962 1156 354 1470 876 136
TT 239 308 106 413 212 33
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Data for CRP and leptin levels as well as BMI were sum-
marized and analyzed by allele score for both CRP- and
adiposity-associated SNPs (Table 2). CRP allele score
demonstrated a decrease in CRP levels with each incre-
ment in allele score. Indeed, participants with a score of 4
(n20) hadon average a 2mg/liter lower circulatingCRP
level compared with those with a score of zero (n 2615)
[3.45 (SD  3.02 mg/liter) vs. 1.47 mg/liter (SD  2.67
mg/liter) P for trend  0.0001]. However, the CRP SNP
allele score demonstrated no association with BMI (P for
trend 0.89) or leptin (P for trend 0.98). Given linkage
disequilibrium between the CRP SNPs, we performed a
sensitivity analysis to validate the simple allele score ap-
proach for these CRP SNPs. Each allele was weighted by
its -coefficient in a regression analysis. Using this ap-
proach, the p for trend across weighted CRP allele score
for CRP levels was 0.0001 (directly comparable to sim-
ple allele count in Table 2). Likewise, weightedCRP allele
scores for BMI and leptin gave nearly identical results as
per simple allele scores (data not shown).
Adiposity-associated allele score was associated with
on average a 1.2 kg/m2 difference comparing zero (n 
1310) to 4 (n  46) [26.62 kg/m2 (SD  4.14 kg/m2) vs.
27.89 kg/m2 (SD 4.25 kg/m2); P for trend 0.002], and
the score was also associated with on average an increase
of 5.77 ng/ml in leptin levels [12.77 ng/ml (SD  2.42
ng/ml) vs. 18.54 (SD  2.06); P for trend  0.0027], al-
though this wasmainly due to a large increase in levels for
a score of 4 (n 46) vs. 3 (n 422). Adiposity allele score
was additionally associated with CRP levels, such that
thosewith a score of 4 relative to zero had on average a 1.2
mg/liter higher circulating CRP [2.91 mg/liter (SD  3.07
mg/liter) vs. 4.15 mg/liter (SD  2.64 mg/liter); P for
trend  0.002].
Discussion
Using a contemporary approach that exploits SNPs re-
lated to two different parameters enabled us to tease out
causal directions between CRP and adiposity. This ap-
proach shows clearly that those genetic variants which
lead to higher BMI are associatedwith increased CRP and
leptin levels, whereas genetic variants that give rise to el-
evatedCRP levels do not, in this study, predict higher BMI
or leptin. Given that the genetic variants are theoretically
unrelated to confounding factors and are not subject to
reverse causality, our observations are less likely to be
confounded by other factors, such as social class or smok-
ing, which would be the case in conventional epidemio-
logical approaches (3–5). Our work extends genetic epi-
demiological studies showing that SNPs associated with
elevated circulating levels of CRP are not associated with
insulin resistance or diabetes risk (32). Together with the
present findings, this suggests that increased circulating
CRP is a consequence of an adverse metabolic profile and
is not a cause of it.
A further interesting finding in this study is that the
FTO and MC4R variants are associated with adiposity,
not just in the very young (9, 11) and themiddle-aged (10,
27) but also in elderly participants at elevated vascular risk
in the present study. This finding suggests that these as-
sociations may be remarkably robust throughout life. Re-
cent evidence has suggested that these polymorphisms
may be associated with higher body fat due to an associ-
ated increased calorific intake (9–12). This is a lifestyle
pattern that one may anticipate remains evident through-
out life on the population scale. That noted, the associa-
tions between FTO and MC4R and BMI are perhaps
weaker in the present population than reported previously
TABLE 2. CRP, BMI, and leptin distribution by CRP and adiposity allele score
CRP (mg/liter) BMI (kg/m2) Leptin (ng/ml)
Low CRP polymorphisms
0 (n  2615) 3.45 (3.02) 26.82 (4.24) 13.32 (2.44)
1 (n  2033) 3.15 (2.98)a 26.87 (4.16) 13.35 (2.41)
2 (n  894) 2.40 (3.19)a 26.72 (4.13) 13.13 (2.51)
3 (n  197) 2.02 (3.03)a 26.80 (4.26) 13.76 (2.35)
4 (n  20) 1.47 (2.67)a 27.60 (4.87) 13.29 (2.67)
P value for trend 0.0001 0.89 0.98
P value adjusted for country 0.0001 0.88 0.93
High adiposity polymorphisms
0 (n  1310) 2.91 (3.07) 26.62 (4.14) 12.77 (2.42)
1 (n  2431) 3.06 (3.09) 26.72 (4.18) 13.15 (2.44)
2 (n  1522) 3.18 (3.02)a 27.07 (4.24)a 13.75 (2.44)a
3 (n  422) 3.35 (3.05)a 26.92 (3.99) 13.87 (2.43)
4 (n  46) 4.15 (2.64)a 27.89 (4.25)a 18.54 (2.06)a
P value for trend 0.002 0.002 0.0027
P value adjusted for country 0.0013 0.0014 0.0019
Data are presented as mean (SD). CRP and leptin were analyzed on a log scale and back-transformed for presentation.
a Significant difference (P  0.05) compared to allele score of 0 (unadjusted).
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in younger populations, although this is somewhat spec-
ulative, and requires confirmation in larger general pop-
ulation studies. Lesser effect of FTO and MC4R on adi-
posity in later life could be expected at older ages because
comorbidities are a more important influence on BMI in
the elderly. In this study, associations of SNPs with leptin
generally validated our findings with regard to BMI.
The bidirectional MR approach we have used here il-
lustrates a useful method for exploring the direction of
causality between two tightly correlated biological path-
ways. Both casual and reverse causality pathways can be
examined (33). Clearly, scientific and clinical experiments
examining the consequences of exogenous administration
of inflammatory factors (34) are possible, but such exper-
iments are generally short-term, whereas in vitro studies
are not easily extrapolated to in vivo conditions. By con-
trast, genetic variants are stable over the life course, not
(theoretically) subject to external confounding or reverse
causation (5), and data from large populations can be ob-
tained inexpensively.
Some limitations and strengthsof the study require con-
sideration. Pleiotropy of genetic variants is a potential
source of residual confounding in MR studies unless all
biological pathways have been examined and excluded as
potential sources of bias or been fully adjusted for (3).
FTO and MC4R could have pleiotropic effects on other
metabolic systems independent of their influence on BMI,
and as such we cannot exclude the possibility that these
genetic variants influence circulating levels of CRP inde-
pendently of their effects on BMI. However, the effects on
downstream risk factors that are thought to be causally
influenced by BMI, such as blood pressure (35),metabolic
risk factors (36), and bone mineral density (37) are as
predicted from theobservational associations of BMIwith
these phenotypes. Furthermore, when multiple genetic
variants are associated with a downstream phenotype to
the degree predicted by their influence on BMI, although
they are unlikely to have the same pleiotropic effects, this
provides evidence against spurious associations, as has
been demonstrated with respect to BMI and bone mineral
density (38).
We combined genetic information from separate CRP
SNPs; a previous meta-analysis showed that both
rs1800947and rs1205were independently related toCRP
concentrations (6). In common with our study, variant
alleles for both the rs1800947 and rs1205 SNPs were as-
sociated with lower CRP levels in this meta-analysis (6),
which reassures that our results are externally valid. Al-
though the twomeasuredCRP SNPs are inmoderate link-
age disequilibrium, they maintain independent effects on
CRP levels, and our sensitivity analysis, as above, vali-
dated the use of a simple allele score approach. Although
BMI is a rather indirect indicator of adiposity, especially
in the elderly, we used leptin as a supplementary biochem-
ical measure of percentage fat mass and were reassured to
note that this parameter was also associated with the ad-
iposity allele score, although it must be noted that the
strength of the association of leptin with the allele score
was largely driven by leptin levels in the double homozy-
gote (allele score 4) group. Finally, althoughwe onlymea-
sured CRP and not other markers of inflammation, much
of the relevant literature has concentrated on CRP as a
possible causal agent in vascular and metabolic disease
(19–21), whereas other recent work diminishes this pos-
sibility (32, 37, 39–41). Our findings now extend these
observations by showing that CRP does not lead to adi-
posity per se but is caused by it. This observation in turn
casts further doubt on CRP as a causal agent in insulin
resistance or type 2 diabetes (32).
In conclusion, using a bidirectional genetic approach
that limits confounding, our data support the hypothesis
that elevated CRP levels are generated by greater adipos-
ity, with no evidence that elevations in CRP levels per se
contribute to fat deposition. This extends findings show-
ing that elevated circulating CRP levels do not cause in-
sulin resistance (32). Clearly, future studies should extend
our findings to other inflammation parameters. Finally,
the future use of this methodology could likewise help to
disentangle directions of associations betweenmanyother
risk pathways.
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